Skip to main content
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. — Investor Relations & Filings

Ticker · COYA ISIN · US22407B1089 US Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2026-05-13 Annual Report
Country US United States of America
Listing US COYA

About Coya Therapeutics, Inc.

https://www.coyatherapeutics.com/

Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops proprietary biologics and multi-modality therapies designed to enhance the function of regulatory T cells (Tregs). The company's approach focuses on modulating dysfunctional Tregs to suppress inflammation associated with neurodegenerative, autoimmune, and metabolic diseases. Its lead product candidate, COYA 302, is an investigational biologic combination therapy being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). The pipeline also includes other candidates such as COYA 303, a combination of low-dose Interleukin-2 (IL-2) and a GLP-1 receptor agonist, intended for inflammation-driven diseases.

Recent filings

Filing Released Lang Actions
ARS - Coya Therapeutics, Inc. (0001835022) (Filer)
Annual Report FY 2025
2026-05-13 English
DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer)
Proxy Solicitation & Information Statement
2026-05-13 English
8-K - Coya Therapeutics, Inc. (0001835022) (Filer)
Capital/Financing Update Classification · 87% confidence The document is a Form 8-K (Current Report) disclosing Item 1.01 – Entry Into a Material Definitive Agreement. It summarizes a Sales Agreement with Leerink Partners for an at-the-market equity offering to raise up to $30 million through the sale of common stock. This constitutes a financing activity update. Therefore, it fits the Capital/Financing Update category.
2026-05-12 English
424B5 - Coya Therapeutics, Inc. (0001835022) (Filer)
Capital/Financing Update Classification · 92% confidence The document is a SEC prospectus supplement filed pursuant to Rule 424(b)(5) as part of a shelf registration statement, detailing an at-the-market offering of up to $30,000,000 of common stock. It is a financing document announcing the terms of an equity capital raise rather than a full annual or interim report, management discussion, or proxy. This clearly falls under a Capital/Financing Update.
2026-05-12 English
10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Coya Therapeutics, Inc. (0001835022) (Filer)
Regulatory Filings Classification · 91% confidence The document is a U.S. SEC Form 8-K “Current Report,” describing Items 2.02 (Results of Operations and Financial Condition via a furnished press release) and Item 8.01 (Other Events), with exhibits. This is a regulatory compliance filing rather than a standalone financial report, earnings release, management discussion, or other defined type. It fits the fallback category Regulatory Filings (Code: RNS).
2026-05-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.